Corporate$ANL7:03 AM ET

Adlai Nortye Group's AN4035 to be tested in Phase I trial as monotherapy and with cetuximab

By BORSA NewsroomPublished Oct 15, 2026, 7:03 AM EDTUpdated Oct 15, 2026, 7:17 AM EDT

Adlai Nortye Group announced its drug candidate AN4035 will be evaluated as a monotherapy and in combination with cetuximab in an ongoing global Phase I trial.

Sentimentbullish 65

Bullish · 65 of 100

Impact30

low · stays off the top drivers

Confidence90%

high confidence · single wire

Eventdeveloping

v1 · alerted to followers

WHAT WE KNOW

AN4035 will be evaluated as monotherapy and in combination with cetuximab.
The trial is a global Phase I study.